Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) reached a new 52-week high on Monday after JPMorgan Chase & Co. raised their price target on the stock from $20.00 to $23.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Travere Therapeutics traded as high as $14.33 and last traded at $14.33, with a volume of 249 shares changing hands. The stock had previously closed at $13.48.
Other equities research analysts have also issued reports about the company. Canaccord Genuity Group upped their price objective on Travere Therapeutics from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Barclays upped their price objective on Travere Therapeutics from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Bank of America upped their price objective on Travere Therapeutics from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, September 6th. Guggenheim upgraded Travere Therapeutics from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Monday, September 9th. Finally, Citigroup increased their price target on Travere Therapeutics from $14.00 to $23.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Travere Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.58.
Get Our Latest Analysis on Travere Therapeutics
Insiders Place Their Bets
Hedge Funds Weigh In On Travere Therapeutics
Hedge funds have recently added to or reduced their stakes in the stock. EntryPoint Capital LLC bought a new stake in shares of Travere Therapeutics in the 1st quarter valued at about $32,000. DRW Securities LLC acquired a new stake in Travere Therapeutics in the second quarter worth $95,000. Forefront Analytics LLC boosted its position in shares of Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after purchasing an additional 1,237 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Travere Therapeutics by 68.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock valued at $113,000 after buying an additional 5,962 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of Travere Therapeutics in the 2nd quarter valued at $117,000.
Travere Therapeutics Trading Up 5.6 %
The company has a fifty day simple moving average of $9.68 and a two-hundred day simple moving average of $7.99. The stock has a market capitalization of $1.09 billion, a P/E ratio of -6.42 and a beta of 0.71. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96.
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. The business had revenue of $54.12 million for the quarter, compared to the consensus estimate of $49.50 million. On average, sell-side analysts expect that Travere Therapeutics, Inc. will post -3.96 earnings per share for the current year.
Travere Therapeutics Company Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Read More
- Five stocks we like better than Travere Therapeutics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Undervalued Stocks That Are Too Cheap to Ignore Right Now
- What Are Dividend Challengers?
- The Analyst Edge: How to Use Expert Opinions
- Market Cap Calculator: How to Calculate Market Cap
- Micron Technology: 4 Reasons to Buy the 44% Price Dip
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.